Research Radartracking 1,311 published studies · 340 human · 8 safety signals · 43 clinical trials · 44 cancer pages · updated Aug 2026Open the Research Map →
Breast Invasive Ductal Carcinoma (IDC): Triple-negative (basal-like)
Last reviewed: 9/15/2025
Applies to: ER–/PR–/HER2– disease.
Summary
Chemo-intensive with immunotherapy in high-risk early disease; ADCs and PARP inhibitors (gBRCA) in metastatic settings.
Pathology & Markers
ER–/PR–/HER2–
PD-L1 CPS subset positive
Biology & Pathways
DNA damage repair defects (gBRCA)
Immune-inflamed microenvironment subset
Clinical Challenges
Higher early relapse risk; brain and visceral metastases.
Need for pCR-oriented neoadjuvant therapy and adjuvant adaptation.
Imaging Notes
Baseline staging for stage II–III; brain MRI if neuro symptoms.